title: Development of PROSTVAC immunotherapy in prostate cancer.
abstract: PROSTVAC immunotherapy is a heterologous prime-boost regimen of two different recombinant pox-virus vectors; vaccinia as the primary immunotherapy, followed by boosters employing fowlpox, to provoke immune responses against prostate-specific antigen. Both vectors contain transgenes for prostate-specific antigen and a triad of T-cell costimulatory molecules (TRICOM). In a placebo-controlled Phase II trial of men with minimally symptomatic, chemotherapy-naive metastatic castration-resistant prostate cancer, PROSTVAC was well tolerated and associated with a 44% reduction in death. With a novel mechanism of action, and excellent tolerability, PROSTVAC has the potential to dramatically alter the treatment landscape of prostate cancer, not only as a monotherapy, but also in combination with other novel agents, such as immune check point inhibitors and novel androgen receptor blockers. A Phase III trial recently completed accrual.
authors.affiliation: Department of Medicine, University of Arizona Cancer Center,1515 N Campbell Avenue, Tucson, AZ, USA.
authors.forename: Parminder
authors.initials: P
authors.lastname: Singh
authors.affiliation: Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center,1500 Duarte Rd, Duarte, CA, USA.
authors.forename: Sumanta K
authors.initials: SK
authors.lastname: Pal
authors.affiliation: Division of Medical Oncology, Department of Medicine, University of Utah Huntsman Cancer Institute, 1950 Circle of Hope, Salt Lake City, UT 84112, USA.
authors.forename: Anitha
authors.initials: A
authors.lastname: Alex
authors.affiliation: Division of Medical Oncology, Department of Medicine, University of Utah Huntsman Cancer Institute, 1950 Circle of Hope, Salt Lake City, UT 84112, USA.
authors.forename: Neeraj
authors.initials: N
authors.lastname: Agarwal
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D019496:Cancer Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005822:Genetic Vectors; D006801:Humans; D007167:Immunotherapy; D000074324:Ipilimumab; D008297:Male; D017430:Prostate-Specific Antigen / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D011944:Receptors, Androgen / Q000235:genetics
chemical_list: C410798:AR protein, human; D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D000074324:Ipilimumab; C588274:PROSTVAC; D011944:Receptors, Androgen; D017430:Prostate-Specific Antigen
keywords: PROSTVAC; pox virus immunotherapy; prostate cancer